Literature DB >> 31564454

Inhibition of Type III CRISPR-Cas Immunity by an Archaeal Virus-Encoded Anti-CRISPR Protein.

Yuvaraj Bhoobalan-Chitty1, Thomas Baek Johansen2, Nadia Di Cianni2, Xu Peng3.   

Abstract

Bacteria and archaea possess a striking diversity of CRISPR-Cas systems divided into six types, posing a significant barrier to viral infection. As part of the virus-host arms race, viruses encode protein inhibitors of type I, II, and V CRISPR-Cas systems, but whether there are natural inhibitors of the other, mechanistically distinct CRISPR-Cas types is unknown. Here, we present the discovery of a type III CRISPR-Cas inhibitor, AcrIIIB1, encoded by the Sulfolobus virus SIRV2. AcrIIIB1 exclusively inhibits CRISPR-Cas subtype III-B immunity mediated by the RNase activity of the accessory protein Csx1. AcrIIIB1 does not appear to bind Csx1 but, rather, interacts with two distinct subtype III-B effector complexes-Cmr-α and Cmr-γ-which, in response to protospacer transcript binding, are known to synthesize cyclic oligoadenylates (cOAs) that activate the Csx1 "collateral" RNase. Taken together, we infer that AcrIIIB1 inhibits type III-B CRISPR-Cas immunity by interfering with a Csx1 RNase-related process.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AcrIIIB; CRISPR-Cas type III accessory RNase; Cmr; Cmr2 (Cas10); anti-CRISPR; cell dormancy; collateral RNA degradation; middle/late viral genes

Mesh:

Substances:

Year:  2019        PMID: 31564454     DOI: 10.1016/j.cell.2019.09.003

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  27 in total

1.  New virus isolates from Italian hydrothermal environments underscore the biogeographic pattern in archaeal virus communities.

Authors:  Diana P Baquero; Patrizia Contursi; Monica Piochi; Simonetta Bartolucci; Ying Liu; Virginija Cvirkaite-Krupovic; David Prangishvili; Mart Krupovic
Journal:  ISME J       Date:  2020-04-22       Impact factor: 10.302

Review 2.  Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins.

Authors:  Ning Jia; Dinshaw J Patel
Journal:  Nat Rev Mol Cell Biol       Date:  2021-06-04       Impact factor: 94.444

Review 3.  Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.

Authors:  Tina Y Liu; Jennifer A Doudna
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

Review 4.  Structures and Strategies of Anti-CRISPR-Mediated Immune Suppression.

Authors:  Tanner Wiegand; Shweta Karambelkar; Joseph Bondy-Denomy; Blake Wiedenheft
Journal:  Annu Rev Microbiol       Date:  2020-06-05       Impact factor: 15.500

5.  CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.

Authors:  Ping Lin; Shugang Qin; Qinqin Pu; Zhihan Wang; Qun Wu; Pan Gao; Jacob Schettler; Kai Guo; Rongpeng Li; Guoping Li; Canhua Huang; Yuquan Wei; George Fu Gao; Jianxin Jiang; Min Wu
Journal:  Mol Cell       Date:  2020-04-28       Impact factor: 17.970

6.  Machine learning predicts new anti-CRISPR proteins.

Authors:  Simon Eitzinger; Amina Asif; Kyle E Watters; Anthony T Iavarone; Gavin J Knott; Jennifer A Doudna; Fayyaz Ul Amir Afsar Minhas
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

7.  A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity.

Authors:  Alexander J Meeske; Ning Jia; Alice K Cassel; Albina Kozlova; Jingqiu Liao; Martin Wiedmann; Dinshaw J Patel; Luciano A Marraffini
Journal:  Science       Date:  2020-05-28       Impact factor: 47.728

Review 8.  Evolutionary Ecology and Interplay of Prokaryotic Innate and Adaptive Immune Systems.

Authors:  Tatiana Dimitriu; Mark D Szczelkun; Edze R Westra
Journal:  Curr Biol       Date:  2020-10-05       Impact factor: 10.834

Review 9.  The arms race between bacteria and their phage foes.

Authors:  Hannah G Hampton; Bridget N J Watson; Peter C Fineran
Journal:  Nature       Date:  2020-01-15       Impact factor: 49.962

Review 10.  Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies.

Authors:  Rafael Pinilla-Redondo; Bálint Csörgő; Nicole D Marino; Joseph Bondy-Denomy
Journal:  Nat Methods       Date:  2020-03-16       Impact factor: 28.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.